Why the study?
Does dabigatran etexilate prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation compared to warfarin?
Does dabigatran etexilate prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation compared to warfarin?
Dabigatran etexilate provides a superior alternative to warfarin for stroke prevention in non-valvular atrial fibrillation, offering effective anticoagulation without the need for routine monitoring or dietary restrictions.
May support dabigatran 150 mg BID over warfarin in non-valvular AF; leaves open need for prospective validation in routine practice.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ohmura et al. (2011) conducted a review in Non-valvular atrial fibrillation (n=18,113). Dabigatran etexilate vs. Warfarin (target PT-INR 2.0-3.0) was evaluated on Stroke or systemic embolism (HR 0.66, 95% CI 0.53-0.82, p=<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: